Shortage of Abatacept (Orencia®) Resolved – update
Update: August 28, 2024.
Bristol Myers Squibb (BMS), the manufacturer of Orencia (abatacept), has announced that the shortage of subcutaneous abatacept will be resolved as of the 30 August 2024.
Starting from 30 August 2024:
- The TGA medicine shortage notification for abatacept 125 mg single dose syringe will no longer be in place.
- The abatacept 125 mg single-dose syringe, BMS, China Stock approved under Section 19A will no longer be available.
- Normal ordering processes for both abatacept pre-filled syringe and ClickJect autoinjector can resume via the DHL online portal.
- Patients may switch back to, or new patients may be initiated on, any of the abatacept presentations as deemed appropriate by the treating physician.
Patients should consult with their healthcare providers for further information.
Discover more...
-
Men’s Health Week: The Reality of Arthritis for Australian Men – what the numbers say
Having arthritis is tough. But is pushing through pain really a badge of honour? This Men’s Health Week, it’s time for a reality check. The...
-
Partnering for progress – Reset rheumatoid arthritis
Arthritis Australia is proud to be a key partner in the RESET RA project, which is developing immunotherapy that could revolutionise the treatment for rheumatoid...
-
National Research Program information session for researchers
We are committed to improving the lives of Australians living with arthritis and musculoskeletal conditions through impactful, relevant research. We’re excited to announce our new...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
